Workflow
中国呼吸道合胞病毒（RSV）疫苗行业市场规模测算逻辑模型 头豹词条报告系列
Tou Bao Yan Jiu Yuan·2024-10-15 12:00

Investment Rating - The report does not explicitly state an investment rating for the RSV vaccine industry in China Core Insights - The RSV vaccine market in China is projected to grow significantly, with estimates indicating a market size of approximately 176.64 billion RMB by 2026, increasing to 255.29 billion RMB by 2030, reflecting a compound annual growth rate (CAGR) of around 9.50% [21][24] - The penetration rate for RSV vaccination among the population aged 60 and above is expected to reach 3.5% by 2026 and increase to 5% by 2030, indicating a growing acceptance and need for vaccination in this demographic [40][44] - The RSV vaccine price is estimated to stabilize at around 1,500 RMB per dose once it is commercially available in China [43][52] Summary by Sections Market Size Estimation - The total population of China is projected to grow at a CAGR of 0.17% from 2018 to 2030, reaching approximately 143.06 million by 2030 [23][24] - The population aged 60 and above is expected to increase from 251.57 million in 2018 to 319.02 million by 2030, representing a significant market for RSV vaccines [25][44] RSV Vaccine Market for the Elderly - The market space for RSV vaccines targeting the population aged 60 and above is projected to grow from 0 billion RMB in 2018 to 255.29 billion RMB by 2030, with a notable increase in growth rates in the coming years [21][24] Newborn Population and RSV Vaccine Market - The newborn population in China is expected to decline from 15.26 million in 2018 to approximately 3.56 million by 2030, which will impact the potential market for RSV vaccines among infants [50][52] - The RSV vaccination penetration rate for newborns is projected to reach 30% by 2030, indicating a growing focus on immunization in early life [51][52] Pricing and Economic Factors - The estimated price for the RSV vaccine is set at 1,500 RMB per dose, which is consistent across the forecasted years from 2026 to 2030 [43][52] - The report highlights that the RSV vaccine market is influenced by the overall demographic trends and the increasing healthcare needs of an aging population [40][44]